Confirmed
Hinrich Abken
Univ.-Prof. Dr med.
University Hospital Regensburg
Leibniz Institute for Immunotherapy
Regensburg, GERMANY
Professor Dr. Hinrich Abken holds the Chair for Genetic Immunotherapy at the University Regensburg and is Director at Leibniz Institute for Immunotherapy (LIT). Dr. Abken studied medicine at the Medical School Essen University, performed his doctoral research studies at the Institute for Molecular Biology, and was post-doc at the Institute for Cell Biology (Prof Rajewsky) in 1983-1987 where he worked on non-coding DNA elements. In 1987-1993 Dr Abken was C1 group leader at the Institute for Genetics (Prof Willecke) and received his venia legendi in Genetics and Immunology from the Faculty of Science of the Rheinische Wilhelms Universität Bonn. In the same year he became C3 University Professor for Tumor Genetics (tenured) at the Medical Faculty of the University of Cologne and was member of the Center for Molecular Medicine Cologne (CMMC) with an Independent Research Group in 1994-2018. During his time at Cologne University Dr Abken pinoeered research on chimeric antigen receptor (CAR) redirected T cells. In June 2018 Dr Abken accepted the Professorship and Chair for Genetic Immunotherapy at the University Regensburg and joined the Regensburg Center for Intervential Immunology (RCI), now Leibniz Institute for Immunotherapy (LIT).
Mascha Binder
Prof. Dr med.
University Hospital Halle (Saale)
University Hospital and Polyclinic for Internal Medicine IV (Haematology and Oncology)
Halle (Saale), GERMANY
CV of Dr Breithaupt-Grögler
Dr. Kerstin Breithaupt-Grögler (MD) studied medicine at J.W. Goethe-University Frankfurt, Germany (1976‑1983). After state approval as physician and medical thesis (doctor of medicine, summa cum laude) worked as Junior Research Fellow at Center of Physiology, University Frankfurt (1983-1985).
From 1986 to 1995 Research Physician / Clinical Investigator at Center of Cardiovascular Pharmacology, Mainz-Wiesbaden, Germany and Board Certification in Clinical Pharmacology. Since 1995 working as independent consultant in clinical pharmacology and medical writer. More than 20 years experience in planning, conduct, evaluation and reporting of clinical trials, writing of expert reports including safety dossiers, clinical summaries / overviews, scientific presentation and publication (30 original papers, more than 80 abstracts and oral presentations).
Founding member of the German Association of Applied Human Pharmacology (AGAH e.V., Hamburg), Board Member since 1997; President 2012-2014, Past President 2014-2018, since 2018 AGAH Regent / Consultant to the AGAH Board. AGAH Delegate to EUFEMED (European Federation for Exploratory Medicines Development, Brussels). Member of scientific programme committees, conduct of workshops and conferences, training courses in exploratory medicines development, qualification of study teams.
Catherine Bollard
Prof.
Center for Cancer & Immunology Research
Children’s National Hospital
Washington, DC, USA
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Dominique Bonnet
Prof.
The Francis Crick Institute
London, UNITED KINGDOM
CV of Dr Abdul-Ahad
Dr Abdul-Ahad was born in Baghdad and obtained his Bachelor’s degrees in Medicine and Surgery from Baghdad Medical School.
After his PhD in Cancer Immunotherapy from Southampton University, he worked at the Children’s Bone Marrow Transplantation Unit, Westminster Hospital conducting pioneering work in children with Leukaemia’s and various genetic disorders. From clinical practice Dr bdul-Ahad transferred to the pharmaceutical industry where he has played many different roles. He was the first to use a therapeutic antibody to treat cancer.
For the last 20 years Ayad has led Global Clinical Development and Medical Affairs of several drugs and vaccines, working in the US, Switzerland and the EU and has been involved in over 300 clinical trials.
Marina Cavazanna
Prof. Dr
Hôpital Necker-Enfants Malades
Département de biothérapie
Paris, FRANCE
Marina CAVAZZANA main research and clinical interests are the development of the hematopoietic immune system, and cell and gene therapy for inherited and acquired disease of the hematopoietic system. Her group studies the means to improve the clinical results of hematopoietic stem cell transplantation, crossing HLA-barriers, and the differentiation of mouse and human stem cells towards lymphocyte lineages. She has initiated several clinical trials based on the use of ex vivo gene modified hematopoietic stem cells to treat patients with inherited disorders, the preliminary clinical results of which are encouraging. Her work was rewarded by the American Society of Hematology (Award on Clinical Research in Gene Therapy in 1999), by the French Academy of Sciences (Special Medical Award in 2000 and Jean-Pierre Lecocq Award on Gene Therapy in 2004). She was awarded the title of Officier de l'Ordre National de la Légion d'honneur in 2011, and given the Irène Joliot Curie 2012 award "Scientific Women of the Year" (Science Academy and French Ministry of Education and Research). She was also awarded with the French National Academy of Medicine in 2016 and the 2017 Ernest Beutler Lecture and Prize for Clinical Science (American Society of Hematology). She has also been elected as an International member of the National Academy of Medicine in 2019.
Ruud Delwel
Prof.
Erasmus University Medical Center
Rotterdam, THE NETHERLANDS
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Cynthia Dunbar
Dr
NIH National Institute of Health
Bethesda, MD, USA
Cynthia Dunbar is a physician-scientist at the National Institutes of Health focused on translational and clinical research in the areas of hematopoiesis, bone marrow failure, natural killer cells, and gene therapies, utilizing non-human primate models to provide insights not possible from small animal or in vitro studies.
Marieke Essers
Dr
German Cancer Research Center (DKFZ)
Heidelberg, GERMANY
CV of Dr Breithaupt-Grögler
Dr. Kerstin Breithaupt-Grögler (MD) studied medicine at J.W. Goethe-University Frankfurt, Germany (1976‑1983). After state approval as physician and medical thesis (doctor of medicine, summa cum laude) worked as Junior Research Fellow at Center of Physiology, University Frankfurt (1983-1985).
From 1986 to 1995 Research Physician / Clinical Investigator at Center of Cardiovascular Pharmacology, Mainz-Wiesbaden, Germany and Board Certification in Clinical Pharmacology. Since 1995 working as independent consultant in clinical pharmacology and medical writer. More than 20 years experience in planning, conduct, evaluation and reporting of clinical trials, writing of expert reports including safety dossiers, clinical summaries / overviews, scientific presentation and publication (30 original papers, more than 80 abstracts and oral presentations).
Founding member of the German Association of Applied Human Pharmacology (AGAH e.V., Hamburg), Board Member since 1997; President 2012-2014, Past President 2014-2018, since 2018 AGAH Regent / Consultant to the AGAH Board. AGAH Delegate to EUFEMED (European Federation for Exploratory Medicines Development, Brussels). Member of scientific programme committees, conduct of workshops and conferences, training courses in exploratory medicines development, qualification of study teams.
Christos Georgiadis
PhD
Great Ormond Street Hospital for Children NSH Trust
UCL Great Ormond Street Institute of Child Health
London, UNITED KINGDOM
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Irmela Jeremias
Prof. Dr
Helmholtz Centre Munich
Munich, GERMANY
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Jan-Henning Klusmann
Prof. Dr
Frankfurt University Hospital
University Centre for Tumour Diseases Frankfurt
Frankfurt, GERMANY
CV of Dr Abdul-Ahad
Dr Abdul-Ahad was born in Baghdad and obtained his Bachelor’s degrees in Medicine and Surgery from Baghdad Medical School.
After his PhD in Cancer Immunotherapy from Southampton University, he worked at the Children’s Bone Marrow Transplantation Unit, Westminster Hospital conducting pioneering work in children with Leukaemia’s and various genetic disorders. From clinical practice Dr bdul-Ahad transferred to the pharmaceutical industry where he has played many different roles. He was the first to use a therapeutic antibody to treat cancer.
For the last 20 years Ayad has led Global Clinical Development and Medical Affairs of several drugs and vaccines, working in the US, Switzerland and the EU and has been involved in over 300 clinical trials.
Rafael Kramann
Prof. Dr.
RWTH Aachen University
Institute of Experimental Medicine
and Systems Biology
Senior Attending Physician Division of Nephrology
Aachen, GERMANY
CV of Dr Breithaupt-Grögler
Dr. Kerstin Breithaupt-Grögler (MD) studied medicine at J.W. Goethe-University Frankfurt, Germany (1976‑1983). After state approval as physician and medical thesis (doctor of medicine, summa cum laude) worked as Junior Research Fellow at Center of Physiology, University Frankfurt (1983-1985).
From 1986 to 1995 Research Physician / Clinical Investigator at Center of Cardiovascular Pharmacology, Mainz-Wiesbaden, Germany and Board Certification in Clinical Pharmacology. Since 1995 working as independent consultant in clinical pharmacology and medical writer. More than 20 years experience in planning, conduct, evaluation and reporting of clinical trials, writing of expert reports including safety dossiers, clinical summaries / overviews, scientific presentation and publication (30 original papers, more than 80 abstracts and oral presentations).
Founding member of the German Association of Applied Human Pharmacology (AGAH e.V., Hamburg), Board Member since 1997; President 2012-2014, Past President 2014-2018, since 2018 AGAH Regent / Consultant to the AGAH Board. AGAH Delegate to EUFEMED (European Federation for Exploratory Medicines Development, Brussels). Member of scientific programme committees, conduct of workshops and conferences, training courses in exploratory medicines development, qualification of study teams.
Sonja Loges
Prof.Dr Dr med.
University Medicine Mannheim
Mannheim Medical Faculty of the University of Heidelberg
Heidelberg, GERMANY
CV of Dr Abdul-Ahad
Dr Abdul-Ahad was born in Baghdad and obtained his Bachelor’s degrees in Medicine and Surgery from Baghdad Medical School.
After his PhD in Cancer Immunotherapy from Southampton University, he worked at the Children’s Bone Marrow Transplantation Unit, Westminster Hospital conducting pioneering work in children with Leukaemia’s and various genetic disorders. From clinical practice Dr bdul-Ahad transferred to the pharmaceutical industry where he has played many different roles. He was the first to use a therapeutic antibody to treat cancer.
For the last 20 years Ayad has led Global Clinical Development and Medical Affairs of several drugs and vaccines, working in the US, Switzerland and the EU and has been involved in over 300 clinical trials.
Andreas Mackensen
Prof.Dr med.
University Hospital Erlangen
Haematology & Internal Oncology/ Medical Clinic 5
Erlangen, GERMANY
Prof. Andreas Mackensen is full professor for Hematology/Oncology and Director of the Dept. of Internal Medicine 5 – Hematology/Oncology at the University of Erlangen. Since 2020, Prof. Mackensen is the director of the Bavarian Center for Cancer Research (BZKF). His research focus is on T-cell based immunotherapy (CAR-T cells) in malignant and autoimmune diseases.
Simon Mendez-Ferrer
Prof.
University of Cambridge and
National Health Service Blood and Transplant
Stem Cell Institute and Department of Haematology
Cambridge, UNITED KINGDOM
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Carsten Müller-Tidow
Prof.Dr med.
Heidelberg University Hospital
Department of Haematology, Oncology and Rheumatology, Internal Medicine V
Heidelberg, GERMANY
CV of Dr Abdul-Ahad
Dr Abdul-Ahad was born in Baghdad and obtained his Bachelor’s degrees in Medicine and Surgery from Baghdad Medical School.
After his PhD in Cancer Immunotherapy from Southampton University, he worked at the Children’s Bone Marrow Transplantation Unit, Westminster Hospital conducting pioneering work in children with Leukaemia’s and various genetic disorders. From clinical practice Dr bdul-Ahad transferred to the pharmaceutical industry where he has played many different roles. He was the first to use a therapeutic antibody to treat cancer.
For the last 20 years Ayad has led Global Clinical Development and Medical Affairs of several drugs and vaccines, working in the US, Switzerland and the EU and has been involved in over 300 clinical trials.
John Pimanda
Prof.
University of New South Wales
Lowy Cancer Research Center
Sydney, AUSTRALIA
CV of Dr Breithaupt-Grögler
Dr. Kerstin Breithaupt-Grögler (MD) studied medicine at J.W. Goethe-University Frankfurt, Germany (1976‑1983). After state approval as physician and medical thesis (doctor of medicine, summa cum laude) worked as Junior Research Fellow at Center of Physiology, University Frankfurt (1983-1985).
From 1986 to 1995 Research Physician / Clinical Investigator at Center of Cardiovascular Pharmacology, Mainz-Wiesbaden, Germany and Board Certification in Clinical Pharmacology. Since 1995 working as independent consultant in clinical pharmacology and medical writer. More than 20 years experience in planning, conduct, evaluation and reporting of clinical trials, writing of expert reports including safety dossiers, clinical summaries / overviews, scientific presentation and publication (30 original papers, more than 80 abstracts and oral presentations).
Founding member of the German Association of Applied Human Pharmacology (AGAH e.V., Hamburg), Board Member since 1997; President 2012-2014, Past President 2014-2018, since 2018 AGAH Regent / Consultant to the AGAH Board. AGAH Delegate to EUFEMED (European Federation for Exploratory Medicines Development, Brussels). Member of scientific programme committees, conduct of workshops and conferences, training courses in exploratory medicines development, qualification of study teams.
Liane Preußner
Dr med.
BioNTech SE
Mainz, GERMANY
CV of Dr Abdul-Ahad
Dr Abdul-Ahad was born in Baghdad and obtained his Bachelor’s degrees in Medicine and Surgery from Baghdad Medical School.
After his PhD in Cancer Immunotherapy from Southampton University, he worked at the Children’s Bone Marrow Transplantation Unit, Westminster Hospital conducting pioneering work in children with Leukaemia’s and various genetic disorders. From clinical practice Dr bdul-Ahad transferred to the pharmaceutical industry where he has played many different roles. He was the first to use a therapeutic antibody to treat cancer.
For the last 20 years Ayad has led Global Clinical Development and Medical Affairs of several drugs and vaccines, working in the US, Switzerland and the EU and has been involved in over 300 clinical trials.
Michael Schmitt
Prof.Dr med.
Heidelberg University Hospital
Department of Haematology, Oncology and Rheumatology, Internal Medicine V
Heidelberg, GERMANY
Cellular Immunotherapy, Department of Medicine V, University Clinic and University of Heidelberg, Heidelberg, Germany
Michael Schmitt, MD, PhD is currently Siebeneicher-Endowment Professor of Cellular Immunotherapy and Head of the Good Manufacturing Practice (GMP) Facility at the University Clinic Heidelberg, Germany. He obtained his MD from the University of the Saarland, Homburg, Germany. At the Universities of Nagasaki and Mie, Japan he was introduced to the field of Tumor Immunology by Prof. H. Shiku. At the University of Ulm, Germany, Dr. Schmitt was trained by Prof. H. Döhner in Internal Medicine and Hematology/Oncology as well as in Stem Cell Transplantation by Prof. D. Bunjes. At the University of Rostock he served as Director of the Stem Cell Transplantation Program before he was appointed to his current position in Heidelberg. His main focus is on cell therapy with chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tolerance induction by cells, cancer vaccines, and stem cell mobilization. Dr. Schmitt obtained the Novartis Research Prize in 1999, the Felix Skubiszewski Medal of the Medical University of Lublin in 2005 as well as the Hans-Jochen Illiger Memorial Prize in 2008.
Prof. Schmitt is currently the Head of the Cellular Therapy Working Party of the German Lymphoma Alliance (GLA) and the German Society for Hematology and Oncology (DGHO).
Rebekka Schneider-Kramann
Prof.Dr
RWTH Aachen University
Institute for Biomedical Technologies – Cell Biology
Aachen, GERMANY
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Axel Schambach
Prof.Dr
Hanover Medical School
Institute of Experimental Haematology
Hanover, GERMANY
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Julia Skokowa
Prof.Dr med.
University Hospital Tuebingen
Internal Medicine II – Haematology, Oncology, Clinical Immunology and Rheumatology
Tuebingen, GERMANY
Julia Skokowa is a full professor in Translational Oncology, Department Internal Medicine II, and the director of Gene Therapy Center, University Hospital Tübingen, Germany.  Her research interests are understanding myeloid differentiation and leukemogenic transformation in pre-leukemia bone marrow failure syndromes, and developing gene therapy approaches using advanced disease modeling.
Christian Steidl
Dr
BC Cancer Research Institute
Vancouver, CANADA
CV of Dr Breithaupt-Grögler
Dr. Kerstin Breithaupt-Grögler (MD) studied medicine at J.W. Goethe-University Frankfurt, Germany (1976‑1983). After state approval as physician and medical thesis (doctor of medicine, summa cum laude) worked as Junior Research Fellow at Center of Physiology, University Frankfurt (1983-1985).
From 1986 to 1995 Research Physician / Clinical Investigator at Center of Cardiovascular Pharmacology, Mainz-Wiesbaden, Germany and Board Certification in Clinical Pharmacology. Since 1995 working as independent consultant in clinical pharmacology and medical writer. More than 20 years experience in planning, conduct, evaluation and reporting of clinical trials, writing of expert reports including safety dossiers, clinical summaries / overviews, scientific presentation and publication (30 original papers, more than 80 abstracts and oral presentations).
Founding member of the German Association of Applied Human Pharmacology (AGAH e.V., Hamburg), Board Member since 1997; President 2012-2014, Past President 2014-2018, since 2018 AGAH Regent / Consultant to the AGAH Board. AGAH Delegate to EUFEMED (European Federation for Exploratory Medicines Development, Brussels). Member of scientific programme committees, conduct of workshops and conferences, training courses in exploratory medicines development, qualification of study teams.
Ulrich Steidl
Prof.
Albert Einstein College of Medicine
New York, UNITED STATES
CV of Dr Caplain
Dr. Henri Caplain, MD, MSc is a physician, senior adviser in early clinical development strategy and drug risk management. He is the past President of the ‘Association Française de Pharmacologie Translationnelle (AFPT) - Le Club Phase 1’ founding member of EUFEMED. After 15 years as primary investigator for early phase clinical trials and medical scientific director within an International CRO ‘Aster-Cephac Group’, he joined Sanofi-Synthelabo Research as head of clinical pharmacology and Exploratory, member of the R&D board. He became associate VP, deputy-head of worldwide clinical pharmacology for Sanofi-Aventis R&D, then head of the risk management center of excellence within Sanofi, member of the Benefit-Risk Assessment Committee chaired by the Sanofi Chief Medical Officer (CMO).
Dan Tenen
Prof.
National University of Singapore
Cancer Science Institute of Singapore
Singapore, SINGAPORE
A native Southern Californian, Dr. Tenen has studied gene regulation for the past 4 decades in AML, lung, and liver cancer, and in the past 15 years nuclear long noncoding RNAs in gene regulation, DNA methylation, and DNA replication; and the oncofetal stem cell gene SALL4 in cancer.
Karl Welte
Prof.Dr med.
University Hospital Tuebingen
Tuebingen, GERMANY
CV of Dr Breithaupt-Grögler
Dr. Kerstin Breithaupt-Grögler (MD) studied medicine at J.W. Goethe-University Frankfurt, Germany (1976‑1983). After state approval as physician and medical thesis (doctor of medicine, summa cum laude) worked as Junior Research Fellow at Center of Physiology, University Frankfurt (1983-1985).
From 1986 to 1995 Research Physician / Clinical Investigator at Center of Cardiovascular Pharmacology, Mainz-Wiesbaden, Germany and Board Certification in Clinical Pharmacology. Since 1995 working as independent consultant in clinical pharmacology and medical writer. More than 20 years experience in planning, conduct, evaluation and reporting of clinical trials, writing of expert reports including safety dossiers, clinical summaries / overviews, scientific presentation and publication (30 original papers, more than 80 abstracts and oral presentations).
Founding member of the German Association of Applied Human Pharmacology (AGAH e.V., Hamburg), Board Member since 1997; President 2012-2014, Past President 2014-2018, since 2018 AGAH Regent / Consultant to the AGAH Board. AGAH Delegate to EUFEMED (European Federation for Exploratory Medicines Development, Brussels). Member of scientific programme committees, conduct of workshops and conferences, training courses in exploratory medicines development, qualification of study teams.
Britta Will
Prof.
Albert Einstein College of Medicine
Department of Medicine (Oncology)
Department of Cell Biology
New York, UNITED STATES
CV of Dr Breithaupt-Grögler
Dr. Kerstin Breithaupt-Grögler (MD) studied medicine at J.W. Goethe-University Frankfurt, Germany (1976‑1983). After state approval as physician and medical thesis (doctor of medicine, summa cum laude) worked as Junior Research Fellow at Center of Physiology, University Frankfurt (1983-1985).
From 1986 to 1995 Research Physician / Clinical Investigator at Center of Cardiovascular Pharmacology, Mainz-Wiesbaden, Germany and Board Certification in Clinical Pharmacology. Since 1995 working as independent consultant in clinical pharmacology and medical writer. More than 20 years experience in planning, conduct, evaluation and reporting of clinical trials, writing of expert reports including safety dossiers, clinical summaries / overviews, scientific presentation and publication (30 original papers, more than 80 abstracts and oral presentations).
Founding member of the German Association of Applied Human Pharmacology (AGAH e.V., Hamburg), Board Member since 1997; President 2012-2014, Past President 2014-2018, since 2018 AGAH Regent / Consultant to the AGAH Board. AGAH Delegate to EUFEMED (European Federation for Exploratory Medicines Development, Brussels). Member of scientific programme committees, conduct of workshops and conferences, training courses in exploratory medicines development, qualification of study teams.
Special 50-years of Wilsede LECTURE
Harald zur Hausen
Prof.
Nobel laureate and Wilsede pioneer
Deutsches Krebsforschungszentrum
Stiftung des öffentlichen Rechts
German Cancer Research Center
Heidelberg, GERMANY
CV of Dr Abdul-Ahad
Dr Abdul-Ahad was born in Baghdad and obtained his Bachelor’s degrees in Medicine and Surgery from Baghdad Medical School.
After his PhD in Cancer Immunotherapy from Southampton University, he worked at the Children’s Bone Marrow Transplantation Unit, Westminster Hospital conducting pioneering work in children with Leukaemia’s and various genetic disorders. From clinical practice Dr bdul-Ahad transferred to the pharmaceutical industry where he has played many different roles. He was the first to use a therapeutic antibody to treat cancer.
For the last 20 years Ayad has led Global Clinical Development and Medical Affairs of several drugs and vaccines, working in the US, Switzerland and the EU and has been involved in over 300 clinical trials.
Special Guests
Carol Stocking-Harbers
Dr
CV of Dr Abdul-Ahad
Dr Abdul-Ahad was born in Baghdad and obtained his Bachelor’s degrees in Medicine and Surgery from Baghdad Medical School.
After his PhD in Cancer Immunotherapy from Southampton University, he worked at the Children’s Bone Marrow Transplantation Unit, Westminster Hospital conducting pioneering work in children with Leukaemia’s and various genetic disorders. From clinical practice Dr bdul-Ahad transferred to the pharmaceutical industry where he has played many different roles. He was the first to use a therapeutic antibody to treat cancer.
For the last 20 years Ayad has led Global Clinical Development and Medical Affairs of several drugs and vaccines, working in the US, Switzerland and the EU and has been involved in over 300 clinical trials.
Axel Zander
Prof. Dr
CV of Dr Breithaupt-Grögler
Dr. Kerstin Breithaupt-Grögler (MD) studied medicine at J.W. Goethe-University Frankfurt, Germany (1976‑1983). After state approval as physician and medical thesis (doctor of medicine, summa cum laude) worked as Junior Research Fellow at Center of Physiology, University Frankfurt (1983-1985).
From 1986 to 1995 Research Physician / Clinical Investigator at Center of Cardiovascular Pharmacology, Mainz-Wiesbaden, Germany and Board Certification in Clinical Pharmacology. Since 1995 working as independent consultant in clinical pharmacology and medical writer. More than 20 years experience in planning, conduct, evaluation and reporting of clinical trials, writing of expert reports including safety dossiers, clinical summaries / overviews, scientific presentation and publication (30 original papers, more than 80 abstracts and oral presentations).
Founding member of the German Association of Applied Human Pharmacology (AGAH e.V., Hamburg), Board Member since 1997; President 2012-2014, Past President 2014-2018, since 2018 AGAH Regent / Consultant to the AGAH Board. AGAH Delegate to EUFEMED (European Federation for Exploratory Medicines Development, Brussels). Member of scientific programme committees, conduct of workshops and conferences, training courses in exploratory medicines development, qualification of study teams.